This is exemplified by the severe neurological disorder that occurred during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 [22] and the psychiatric side effects associated with the cannabinoid receptor 1 (CB1) inverse agonist rimonabant [23]. Here, FAAH is linked to nervous system disorder.